Gossamer Bio, Inc. (GOSS)

NASDAQ • Healthcare

$9.61

+$0.14 (+1.6%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$9.4

Previous Close$9.61

Day Range$9 - $9.77

Avg. Volume (3M)277.1K

Market Cap$58.6M

52 Week Range

$8.29$309.6

Next EarningsIn 10 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$9.2M100%

Gross Profitminus cost of goods$9.2M100%

Net Incomeminus taxes and the rest$16.9M183%

Fundamentals & Financials

Revenue (TTM)

$53.2M

Net Income (TTM)

-$125.2M

EPS (TTM)

-$45.32

ROA (TTM)

-162.91%

Current Ratio

0.53

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+5.6%Q3 2025-$0.17

-10.5%Q4 2025-$0.21

-5.0%Q1 2026-$0.21

-17.6%Q2 2026-$0.2

+35.2%Q3 2026-$6.4

Nov 4

in 10 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +35.2%

Gossamer Bio topped consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, reported August 13, 2026, even as revenue fell year over year. Revenue declined 19.6% to about $9.2 million (down from about $11.5 million a year ago) and, on the consensus tape, came in at $9.2 million versus the $3.6 million estimate (+155%), topped. Adjusted EPS was -$0.20, improving 17.6% from -$0.17 a year ago, and it topped the -$9.87 estimate by $9.67. Profitability remained negative at the operating line, with operating income of roughly -$26.1 million, while gross profit was about $9.2 million in a quarter tied to its pulmonary hypertension pipeline, including seralutinib and GB002. For the next period, consensus calls for EPS of -$3.89 on revenue of $10.7 million.

Next report — what to expect

Gossamer Bio, Inc. (GOSS) reports next on November 4, 2026. Wall Street expects EPS of -$3.934 on revenue of $10.7 million. For trailing context, revenue fell -19.6% year over year last quarter. The company has beaten EPS in 7 of 8 most recent quarters.

View full earnings history

About Gossamer Bio, Inc.

Gossamer Bio, Inc. is a Nasdaq-listed biotechnology company in clinical development, focused on drug candidates for pulmonary hypertension. In FY2025, it recorded $48.5 million in revenue. The company operates in the United States and centers its programs on seralutinib, a therapy for pulmonary hypertension and pulmonary arterial hypertension.

Name

Gossamer Bio, Inc.

CEO

Faheem Hasnain

Website

www.gossamerbio.com

Industry

Healthcare

Year Founded

2015

Employees

162

Today's Snapshot

AI-generated

The day ended with GOSS 1.5% higher at 9.61, outperforming a weaker sector. Trading was lighter than usual, with volume about two-thirds of its usual level. Earnings are due from GOSS on 4 November.

Trading Volume

Below 10d avg (231.4K)

144.7K

vs S&P 500 Today

Outperforming Market

+2.05%

Updated: October 23, 2026 at 20:23 UTC

Technical Indicators

1 Buy3 Neutral4 Sell

Trading near 9.61, GOSS shows a defensive technical profile with a weak trend and mixed momentum. ADX at 16 indicates little directional conviction, while short-term momentum readings are lukewarm—RSI in the mid-40s and MACD slightly negative—despite a small positive momentum reading. Price sits around the short 10-period averages yet remains well below most medium- and long-term moving averages, and on-balance volume is negative, suggesting distribution. Volatility is elevated with an ATR near 10% of price, and the classic pivot is essentially at the current level. Technical takeaway: Sell.

All signals